Are you Dr. Valencia?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 113 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3150 N Tenaya Way
Ste 320
Las Vegas, NV 89128Phone+1 702-240-6482Fax+1 702-804-0957
Summary
- Dr. Rafael Valencia, MD is a cardiologist in Las Vegas, Nevada. He is currently licensed to practice medicine in Nevada, California, and New York. He is affiliated with MountainView Hospital, Summerlin Hospital Medical Center, and Valley Hospital Medical Center.
Education & Training
- Scripps Clinic/Scripps Green HospitalFellowship, Interventional Cardiology, 2005 - 2006
- NYU Grossman School of MedicineFellowship, Cardiovascular Disease, 2002 - 2005
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
- Weill Cornell MedicineClass of 1999
Certifications & Licensure
- NV State Medical License 2007 - 2025
- CA State Medical License 2005 - 2024
- NY State Medical License 2000 - 2005
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification All in One EMR, Medstreaming, 2013
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 521 citationsPrognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.Matthew J. Price, Sarah Endemann, Raghava R. Gollapudi, Rafael Valencia, Curtiss T. Stinis
European Heart Journal. 2008-04-01 - 40 citationsClopidogrel Desensitization After Drug-Eluting Stent PlacementKarl F. von Tiehl, Matthew J. Price, Rafael Valencia, Katherine J. Ludington, Paul S. Teirstein
Journal of the American College of Cardiology. 2007-11-20 - 15 citationsEfficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).Rafael Valencia, Matthew J. Price, Neil Sawhney, Steve S. Lee, Garrett B. Wong
The American Journal of Cardiology. 2007-10-01
Professional Memberships
- Member
Other Languages
- Spanish